---
title: "Sanofi’s New Study on SAR444336: A Potential Breakthrough in Microscopic Colitis Treatment"
description: "Sanofi has launched a clinical study titled ‘A Randomized, Double-blind, Placebo-controlled Study’ to evaluate the efficacy and safety of SAR444336 for treating adults with microscopic colitis in clin"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256171178.md"
published_at: "2025-09-05T16:30:30.000Z"
---

# Sanofi’s New Study on SAR444336: A Potential Breakthrough in Microscopic Colitis Treatment

> Sanofi has launched a clinical study titled ‘A Randomized, Double-blind, Placebo-controlled Study’ to evaluate the efficacy and safety of SAR444336 for treating adults with microscopic colitis in clinical remission. The study aims to assess the drug's effectiveness compared to a placebo, utilizing a quadruple masking approach. Scheduled to start on September 3, 2025, the study's outcomes could significantly impact Sanofi's market position in gastrointestinal treatments and potentially influence stock performance if results are favorable.

Sanofi ((SNYNF)) announced an update on their ongoing clinical study.

### Elevate Your Investing Strategy:

-   Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Sanofi has launched a new clinical study titled ‘A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of SAR444336 in Participants With Microscopic Colitis in Clinical Remission With Budesonide’. The study aims to evaluate the efficacy and safety of SAR444336, a drug designed to treat adults with microscopic colitis who are in clinical remission and currently receiving budesonide therapy. This research is significant as it explores new treatment avenues for a condition that affects the colon, potentially improving patient outcomes.

The intervention being tested is SAR444336, an experimental drug administered via subcutaneous injection. It is compared against a placebo to assess its effectiveness in maintaining remission in patients with microscopic colitis.

The study is designed as a randomized, double-blind, placebo-controlled trial with a parallel-group model. It employs a quadruple masking approach, meaning that participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocations. The primary purpose of this Phase 2 study is treatment-focused.

The study is not yet recruiting, with a start date set for September 3, 2025. The primary completion and estimated completion dates have not been disclosed, but the last update was also on September 3, 2025. These dates are crucial as they mark the progression and timelines for potential results and subsequent phases.

For investors, this study represents a potential advancement in Sanofi’s portfolio, which could positively influence stock performance if the results are favorable. The pharmaceutical industry is competitive, and successful outcomes could enhance Sanofi’s position in the market, particularly in the niche area of gastrointestinal treatments.

The study is ongoing, with further details available on the ClinicalTrials portal.

## Trending Articles:

-   CAPR Lawsuit Alert! Class Action Lawsuit Against Capricor Therapeutics
-   META or GOOGL: Top Analyst Picks the ‘Top Consumer AI Play’
-   Tesla Cuts New Model 3 Prices by 4% in China, While Norway Sales Surge 38%

Disclaimer & DisclosureReport an Issue

### Related Stocks

- [SNYNF.US - Sanofi](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 赛诺菲计划扩展其在印度的全球能力中心 | 赛诺菲计划在印度扩展全球能力中心 | [Link](https://longbridge.com/en/news/276093503.md) |
| 赛诺菲在疫苗巨头的转型受阻后解雇了首席执行官 Hudson | 赛诺菲在经历了六年的任期后，解雇了首席执行官保罗·哈德森，期间公司转型停滞不前，疫苗销售面临压力。哈德森将于 2 月 17 日辞职，由现任默克 KGaA 首席执行官贝伦·加里霍接任，接任时间定于 4 月底。赛诺菲的股价在公告发布后下跌近 6 | [Link](https://longbridge.com/en/news/275748711.md) |
| 无惧特朗普施压，美国 350 种处方药明年提价 | 2026 年在即，美国制药商计划上调超 350 种药物价格，提价规模较往年扩大，中位涨幅约 4%。辉瑞、赛诺菲等头部药企虽与特朗普政府达成了部分降价协议，但仍对新冠疫苗、抗癌药等核心产品涨价。专家表示，尽管政府持续施压，但药企通过提高标价后 | [Link](https://longbridge.com/en/news/271219207.md) |
| 赛诺菲：Beyfortus 研究表明对婴儿在首个 RSV 季节之后仍然有益 | 赛诺菲宣布，其使用 Beyfortus 的 RSV 免疫计划研究显示，在婴儿的第二个 RSV 季节中，RSV 相关住院人数显著减少。发表在《柳叶刀传染病》上的研究结果表明，该免疫计划不仅在第一个季节减少了住院和门诊疾病，还对第二个季节产生了 | [Link](https://longbridge.com/en/news/276038221.md) |
| 赛诺菲印度医疗保健扩展海得拉巴全球能力中心，以提升能力并推动创新 | 赛诺菲印度医疗公司扩展海得拉巴全球交付中心，以增强能力并推动创新 | [Link](https://longbridge.com/en/news/276048003.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.